Premium Essay

Cryopyrin-Associated Periodic Syndromes (CAPS)

Submitted By
Words 771
Pages 4
Cryopyrin-Associated Periodic Syndromes
(CAPS)
A look into an emerging rare genetic disorder: A Case Study

Rebecca Nelson
MLS 465
*The patient history, results, and diagnosis in this case study are real. Patient consent was obtained.

Overview: A healthy female adult made a new patient appointment to be seen who was experiencing joint pain in her right knee, having trouble walking as result, and felt slightly ill (malaise). Patient arrived to physician’s office limping with limited mobility of right knee, the use of crutches was needed for patient to move. Upon examination, the physician noticed raised hives (urticarial rash) on back, stomach, and arms as well as extreme redness in the left eye similar to conjunctivitis. Patient wanted instant relief for joint pain and indicated other symptoms are ‘normal’ and have been consistent symptoms since birth. Patient temperature was 99.0 degrees Fahrenheit.
Full Patient History: Patient was born in a dry desert environment but had spent 8 years in a mountainous city with cold winters. Patient had been back in dry desert environment for 4 months when this appointment was made. Patient has travelled to Nicaragua for two months in 2007 and Costa Rica for 5 weeks in 2009. First indication of symptoms was a full case of urticarial, extreme joint pain, and what the patient described as partial paralysis due to joint pain around the ages of 3-4. Patient did not have medical records but reports tests were completed upon admission to the ER and no diagnosis was made. At the age of 6, patient …show more content…
Patients’ father does not exhibit flu-like symptoms or mouth ulcers. The father’s primary care physician believes his symptoms are not genetic and would not be passed onto children. Father was given an initial diagnosis of urticarial vasculitis and an undiagnosed food

Similar Documents

Free Essay

Monoclonal Antibodies

...ABfocus on THERAPEuTIc AnTIBoDIEs REVIEWS Therapeutic antibodies for autoimmunity and inflammation Andrew C. Chan* and Paul J. Carter‡ Abstract | The development of therapeutic antibodies has evolved over the past decade into a mainstay of therapeutic options for patients with autoimmune and inflammatory diseases. Substantial advances in understanding the biology of human diseases have been made and tremendous benefit to patients has been gained with the first generation of therapeutic antibodies. The lessons learnt from these antibodies have provided the foundation for the discovery and development of future therapeutic antibodies. Here we review how key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibodies with promise for greater clinical efficacy and safety. Effector functions Fc-mediated antibody properties that are involved in target cell destruction: antibody-dependent cell-mediated cytotoxicity (ADCC), antibodydependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). Half-life The time taken for the plasma concentration of a drug to fall to half of its original value. Initial half-life and terminal half-life refer to the first (distribution) and second (elimination) phase for bi-exponential pharmacokinetics, respectively. *Department of Immunology, Genentech, Inc.,1 DNA Way, South San Francisco, California...

Words: 11070 - Pages: 45